SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 167 filers reported holding SAGE THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,450,649 | -67.1% | 167,670 | -24.7% | 0.00% | -62.5% |
| Q2 2023 | $10,475,727 | +19.7% | 222,793 | +6.8% | 0.01% | +14.3% |
| Q1 2023 | $8,751,262 | +11.2% | 208,562 | +1.1% | 0.01% | +16.7% |
| Q4 2022 | $7,870,303 | -1.6% | 206,353 | +1.1% | 0.01% | -14.3% |
| Q3 2022 | $7,996,000 | +35.7% | 204,198 | +11.9% | 0.01% | +40.0% |
| Q2 2022 | $5,892,000 | -39.1% | 182,426 | -37.5% | 0.01% | -28.6% |
| Q1 2022 | $9,668,000 | -29.6% | 292,086 | -9.5% | 0.01% | -22.2% |
| Q4 2021 | $13,737,000 | +1.8% | 322,916 | +6.0% | 0.01% | 0.0% |
| Q3 2021 | $13,497,000 | -18.0% | 304,603 | +5.2% | 0.01% | -18.2% |
| Q2 2021 | $16,450,000 | -37.7% | 289,570 | -17.9% | 0.01% | -42.1% |
| Q1 2021 | $26,411,000 | +46.7% | 352,852 | +69.5% | 0.02% | +35.7% |
| Q4 2020 | $18,008,000 | +33.9% | 208,159 | -5.4% | 0.01% | +16.7% |
| Q3 2020 | $13,447,000 | +47.2% | 220,004 | +0.1% | 0.01% | +33.3% |
| Q2 2020 | $9,138,000 | +44.9% | 219,765 | +0.1% | 0.01% | +12.5% |
| Q1 2020 | $6,308,000 | -90.0% | 219,632 | -74.9% | 0.01% | -86.7% |
| Q4 2019 | $63,129,000 | -37.6% | 874,482 | +21.3% | 0.06% | -40.6% |
| Q3 2019 | $101,114,000 | +7.2% | 720,751 | +39.9% | 0.10% | +7.4% |
| Q2 2019 | $94,349,000 | +4.1% | 515,316 | -9.6% | 0.09% | +2.2% |
| Q1 2019 | $90,647,000 | +78.5% | 569,930 | +7.5% | 0.09% | +58.6% |
| Q4 2018 | $50,778,000 | -19.7% | 530,095 | +18.3% | 0.06% | -6.5% |
| Q3 2018 | $63,267,000 | -23.3% | 447,906 | -15.0% | 0.06% | -25.3% |
| Q2 2018 | $82,501,000 | +59.0% | 527,062 | +63.6% | 0.08% | +56.6% |
| Q1 2018 | $51,902,000 | +977.9% | 322,231 | +1002.2% | 0.05% | +960.0% |
| Q4 2017 | $4,815,000 | +204.9% | 29,236 | +15.4% | 0.01% | +150.0% |
| Q3 2017 | $1,579,000 | -15.2% | 25,343 | +8.4% | 0.00% | 0.0% |
| Q2 2017 | $1,862,000 | -2.2% | 23,384 | -12.7% | 0.00% | 0.0% |
| Q1 2017 | $1,903,000 | +38.5% | 26,771 | -0.5% | 0.00% | +100.0% |
| Q4 2016 | $1,374,000 | -6.9% | 26,919 | -16.0% | 0.00% | -50.0% |
| Q3 2016 | $1,476,000 | – | 32,053 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |